Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Figure 1 Increase of bevacizumab level in serum. Increase of the serum concentration of the drug in function of time; the serum was withdrawn before the 2^nd and the 5^th cycle of therapy. Results are divided in three histograms, representative of the fold change of bevacizumab (BV) in patients who showed partial response (PR), stable disease (SD) and progression disease (PD). ^aP < 0.05, BV of patients with SD or PD vs with PR.